Radiotherapy for Oligometastatic Prostate Cancer

Oligometastatic Prostate Cancer Clinical Trial

Official title: Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer

Status Completed

Clinical Trial Summary

The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.

Clinical Trial Description

This study will serve as a component of a larger program investigating the benefits of stereotactic radiotherapy in patients with metastatic disease. This particular study will serve as a benchmark analysis. All patients will receive stereotactic radiotherapy directed at metastatic tumors. If primary prostate cancer is active and has not previously been treated with radiation therapy, conventional radiation therapy (6-8 weeks of daily treatment) may be recommended. The metastatic tumor will be treated at the same time. Hormone therapy will be recommended for all patients. Patients will be asked to complete questionnaires at regular intervals. ;

Related Conditions & MeSH terms

• Oligometastatic Prostate Cancer
• Prostatic Neoplasms

• NCT number: NCT01859221
• Study type: Interventional
• Source: University of Florida
• Status: Completed
• Phase: N/A
• Start date: May 2013
• Completion date: September 13, 2022